Kestra Advisory Services, LLC Durect Corp Transaction History

Kestra Advisory Services, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	BUY	$0.43 - $5.9 $411 - $5,646	957 Added 9.19%	11,374 $7 Million
Q1 2022 Apr 26, 2022	SELL	$0.55 - $0.98 $67,921 - $121,023	-123,493 Reduced 92.22%	10,417 $6,000
Q4 2021 Jan 20, 2022	SELL	$0.9 - $1.31 $1,226 - $1,785	-1,363 Reduced 1.01%	133,910 $132,000
Q3 2021 Oct 19, 2021	BUY	$1.21 - $1.61 $1,207 - $1,606	998 Added 0.74%	135,273 $173,000
Q2 2021 Jul 28, 2021	BUY	$1.6 - $2.02 $1,526 - $1,927	954 Added 0.72%	134,275 $218,000
Q1 2021 May 10, 2021	BUY	$1.86 - $2.87 $15,188 - $23,436	8,166 Added 6.52%	133,321 $263,000
Q4 2020 Jan 20, 2021	BUY	$1.65 - $2.43 $206,505 - $304,126	125,155 New	125,155 $268 Million

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $171M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.